This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 16-22 July 2023 and includes updates on avian influenza, Echovirus 11, COVID-19, West Nile virus, poliomyelitis, and botulism.
The laboratories participating in the QA21 EQA scheme for antimicrobial susceptibility testing of N. gonorrhoeae showed good levels of competency and capability in recovering and testing strains of unknown phenotype.
The surveillance of Neisseria gonorrhoeae antimicrobial susceptibility in the European Union/European Economic Area (EU/EEA) is essential for detecting emerging and increasing antimicrobial resistance. Since 2009, this surveillance has been co-ordinated by the European Centre for Disease Prevention and Control (ECDC). The quality-assured data produced can be used to inform treatment guidelines.
This evidence brief summarises key issues and priorities for action in Europe and Central Asia on HIV testing. It is largely based on data collected in 2021 by the European Centre for Disease Prevention and Control (ECDC) to monitor implementation of the 2004 Dublin Declaration.
This evidence brief summarises key issues and priorities for action in Europe and Central Asia on PrEP. It is largely based on data collected between March and September 2021 by the European Centre for Disease Prevention and Control (ECDC) to monitor implementation of the 2004 Dublin Declaration.